Clinical Research Directory
Browse clinical research sites, groups, and studies.
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
Sponsor: University of Birmingham
Summary
The aim of this study is to reduce pulmonary complications in adult patients undergoing abdominal or thoracic surgery in COVID-19 exposed hospital environments. A Trial in Low and Middle Income Countries (LMICs)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
281
Start Date
2022-05-16
Completion Date
2023-06-30
Last Updated
2026-11-16
Healthy Volunteers
No
Interventions
RESP301
RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.
Locations (9)
University Of Abuja Teaching Hospital (Spoke)
Gwagwalada, Nigeria
Lagos University Teaching Hospital (Hub)
Lagos, Nigeria
Nnamdi Azikiwe University Teaching Hospital (Spoke)
Nnewi, Nigeria
University Teaching Hospital of Butare (CHUB) (Spoke)
Butare, Rwanda
Kibungo Referral Hospital (Spoke)
Kibungo, Rwanda
Kibagabaga Hospital (Spoke)
Kigali, Rwanda
University Teaching Hospital of Kigali (Hub)
Kigali, Rwanda
Kibogora District Hospital (Spoke)
Kirambo, Rwanda
Ruhengeri Referral Hospital (Spoke)
Ruhengeri, Rwanda